PrairieView Partners’s Pacira BioSciences PCRX Stock Holding History

PrairieView Partners’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$0	Hold	5	–	–	﹤0.01%	385
2025 Q1	$0	Hold	5	–	–	﹤0.01%	381
2024 Q4	$0	Hold	5	–	–	﹤0.01%	381
2024 Q3	$0	Hold	5	–	–	﹤0.01%	403
2024 Q2	$0	Hold	5	–	–	﹤0.01%	395
2024 Q1	$1K	Hold	5	–	–	﹤0.01%	374
2023 Q4	$0	Hold	5	–	–	﹤0.01%	406
2023 Q3	$0	Hold	5	–	–	﹤0.01%	454
2023 Q2	$0	Hold	5	–	–	﹤0.01%	470
2023 Q1	$0	Hold	5	–	–	﹤0.01%	474
2022 Q4	$0	Hold	5	–	–	﹤0.01%	489
2022 Q3	$0	Hold	5	–	–	﹤0.01%	462
2022 Q2	$0	Hold	5	–	–	﹤0.01%	476
2022 Q1	$0	Hold	5	–	–	﹤0.01%	477
2021 Q4	$0	Hold	5	–	–	﹤0.01%	433
2021 Q3	$0	Hold	5	–	–	﹤0.01%	384
2021 Q2	$0	Hold	5	–	–	﹤0.01%	374
2021 Q1	$0	Hold	5	–	–	﹤0.01%	372
2020 Q4	$0	Hold	5	–	–	﹤0.01%	321
2020 Q3	$0	Hold	5	–	–	﹤0.01%	315
2020 Q2	$0	Hold	5	–	–	﹤0.01%	305
2020 Q1	$0	Buy	+5	New	+$208	﹤0.01%	300

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

PrairieView Partners's PCRX Position: Q2 2025 in Review

PrairieView Partners held its Pacira BioSciences (PCRX) position steady in Q2 2025 at 5 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #385.

PrairieView Partners first reported a position in PCRX in Q1 2020 and has held it in 22 quarters since. The position peaked at $1K in Q1 2024. 233 funds tracked by Wall St. Rank hold PCRX as of Q2 2025.

PrairieView Partners held 5 shares of Pacira BioSciences worth $0 as of Q2 2025.
PrairieView Partners left its Pacira BioSciences share count unchanged in Q2 2025.
Pacira BioSciences made up ﹤0.01% of PrairieView Partners's portfolio in Q2 2025, its #385 holding.
PrairieView Partners first reported a position in Pacira BioSciences in Q1 2020 and has held it in 22 quarters since.
PrairieView Partners's Pacira BioSciences position peaked at $1K in Q1 2024.
233 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2025.

Based on PrairieView Partners's 13F filing for Q2 2025, filed 25 Jul 2025.